CRISPR Therapeutics AG: Q2 2025 Financial Summary
Business Context and Reporting Period
This summary covers the quarterly period ended June 30, 2025, for CRISPR Therapeutics AG (CRSP), a leading gene-editing company. The Company operates as a single segment focused on discovering, developing, and commercializing CRISPR-based therapeutics. Key programs include the approved hemoglobinopathy therapy CASGEVY (in collaboration with Vertex), allogeneic CAR T cell therapies (CTX112, CTX131), in vivo gene editing candidates (CTX310, CTX320), and Type 1 Diabetes therapies (CTX211).
Key Financial Metrics
| Metric (in millions) | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Total Revenue | $0.9 | $0.5 | $1.8 | $1.0 |
| Net Loss | $(208.5) | $(126.4) | $(344.5) | $(243.0) |
| Net Loss Per Share (Basic/Diluted) | $(2.40) | $(1.49) | $(3.98) | $(2.92) |
| Operating Expenses | $230.2 | $151.8 | $379.5 | $292.9 |
| Cash, Cash Equivalents & Marketable Securities | $1,721.2 (as of June 30, 2025) | |||
| Accumulated Deficit | $(1,710.5) (as of June 30, 2025) |
Material Changes vs. Prior Period
- Acquired In-Process R&D (IPR&D): Operating expenses increased significantly due to a one-time $96.3 million charge for acquired IPR&D related to the new Sirius Therapeutics collaboration. This charge comprised a $25.0 million upfront cash payment and $71.3 million in stock issuance costs.
- Net Loss Expansion: Net loss for the six months ended June 30, 2025, increased by $101.5 million compared to the prior year period, primarily driven by the Sirius IPR&D charge and a $101.5 million increase in the underlying net loss position.
- Operating Cash Flow: Net cash used in operating activities was $167.8 million for the six months ended June 30, 2025, compared to cash provided by operating activities of $14.2 million in the prior year. This shift was largely due to the timing of receivable collections from Vertex ($25.0 million collected in Q1 2025 vs. $200.0 million in Q1 2024) and the non-cash Sirius expense.
- Revenue: Total revenue remains minimal, derived primarily from grant revenue ($1.8 million YTD 2025). No collaboration revenue was recognized from Vertex or other partners during the period.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management expects existing cash, cash equivalents, and marketable securities ($1.72 billion) to fund operations and capital expenditures for at least the next 24 months without additional financing, excluding potential proceeds from collaborations.
- Strategic Developments:
- Sirius Therapeutics: Entered a collaboration in May 2025 to jointly develop siRNA therapies (SRSD107) targeting Factor XI. The Company will lead commercialization in the U.S., while Sirius leads in Greater China.
- CASGEVY: Collaboration expenses with Vertex decreased in Q2 2025 due to increased revenue share from CASGEVY, though costs associated with the commercial launch remain.
- CTX310: Reported Phase 1 data showing dose-dependent reductions in triglycerides (up to 82%) and LDL (up to 86%) with a favorable safety profile.
- Risks and Contingencies:
- Intellectual Property Litigation: A third-party licensor has engaged the Company regarding potential additional amounts owed under IP contracts. As of June 30, 2025, the Company cannot estimate a reasonably possible loss.
- Tax Legislation: The "One Big Beautiful Bill Act" enacted on July 4, 2025, introduces changes to R&D expenditure treatment. The Company is assessing the impact but has not yet recorded adjustments.
- Capital Needs: While current resources are sufficient for 24 months, long-term development and commercialization will require additional capital, potentially through equity or debt financings.
Key Facts for Investor Verification
- One-Time Charge Impact: Verify the sustainability of operating expenses by excluding the $96.3 million Sirius IPR&D charge to assess core burn rate.
- Cash Runway: Confirm the 24-month liquidity runway assumption, noting it excludes potential future milestone payments from Vertex or other partners.
- Vertex Receivables: Monitor the timing of future milestone or royalty payments from Vertex, as the timing of these collections significantly impacts quarterly operating cash flow.
- IP Litigation Exposure: Track developments regarding the third-party licensor dispute, as the potential liability is currently unquantified.
- ATM Facility: Note that $354.8 million remains available under the 2021 At-The-Market (ATM) offering program, which was utilized for $8.7 million in proceeds during the first half of 2025.